Cyclacel raises $15.2 million as it prepares AML candidate for Phase III
This article was originally published in Scrip
Cyclacel Pharmaceuticals has raised $15.2 million ($14.1 million net) in a private placement of 8.32 million units at $1.82625 each to institutional investors as its lead compound is prepared for Phase III trials. The institutions also have the option to acquire up to an additional 4.16 million units at $1.67 each at any time up to nine months after the closing, which would raise an additional $6.9 million for the company.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.